IDP Pharma has closed a 1,4M€ seed investment round, following a pre-seed round of 0,1M€ (June 2015), which adds up to the ca 0,6M€ funds granted by several public institutions (MINECO, ENISA, CDTI-NEOTEC and ACCIÓ).

The company will allocate the capital to advance the preclinical development of its prioritized product – a first in class drug for multiple mieloma treatment, to set up new discovery programs, and to continue developing its technological platform.

Source: IDP Pharma

Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Indexa Capital Group aumenta sus ingreso...

by Indexa Capital

Indexa Capital Group, sociedad matriz de Indexa Capital AV, Bewater As...

Photos Stream